Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 11, 2013, Pages 2336-2341

  Raviprakash, Kanakatte ^a   Sun, Peifang ^a,b   Raviv, Yossef ^c   Luke, Thomas ^a,b   Martin, Nicholas ^a   Kochel, Tadeusz ^a  

^a NAVAL MEDICAL RESEARCH CENTER   (United States)

^b HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dengue virus; Immunogenicity; Mouse; Vaccine; Virus inactivation

Indexed keywords

1,5 IODONAPHTHYLAZIDE; ALUMINUM POTASSIUM SULFATE; AMINOMETHYL TRIOXSALEN; DENGUE VACCINE; FORMALDEHYDE; MONOCLONAL ANTIBODY; NAPHTHALENE DERIVATIVE; NEUTRALIZING ANTIBODY; PSORALEN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; AMINOMETHYLTRIOXSALEN; AZIDE; DISINFECTANT AGENT; INACTIVATED VACCINE; IODONAPHTHYLAZIDE; TRIOXYSALEN; VIRUS ANTIBODY;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DENGUE VIRUS 2; IMMUNOGENICITY; MOUSE; NONHUMAN; T LYMPHOCYTE; VIRUS ATTACHMENT; VIRUS INACTIVATION; VIRUS PURIFICATION; ANALOGS AND DERIVATIVES; ANIMAL; BAGG ALBINO MOUSE; BLOOD; COMPARATIVE STUDY; DENGUE VIRUS; DRUG EFFECTS; IMMUNOLOGY; LIGHT;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; AZIDES; DENGUE VACCINES; DENGUE VIRUS; DISINFECTANTS; FORMALDEHYDE; LIGHT; MICE, INBRED BALB C; T-LYMPHOCYTES; TRIOXSALEN; VACCINES, INACTIVATED; VIRUS INACTIVATION;

EID: 84887447155     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.25602     Document Type: Article

References (39)

1. Halstead SB. Dengue. Lancet 2007; 370: 1644-52; http://dx.doi.org/10. 1016/S0140-6736(07)61687-0; PMID: 17993365 (Pubitemid 350052290)
2. Simmons CP, Farrar JJ, Nguyen V, Wills B. Dengue. N Engl J Med 2012; 366: 1423-32; http://dx.doi.org/10.1056/NEJMra1110265; PMID: 22494122
3. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am J Trop Med Hyg 1988; 38: 411-9; PMID: 3354774 (Pubitemid 18086128)
4. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg 1989; 40: 444-51; PMID: 2712199 (Pubitemid 19117544)
5. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, Eckels KH, et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin 2009; 5: 33-40; PMID: 18670195; http://dx.doi.org/10.4161/hv.5.1.6348
6. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, Tang D, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 2003; 69(Suppl): 48-60; PMID: 14740955
7. Robert Putnak J, Coller BA, Voss G, Vaughn DW, Clements D, Peters I, et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 2005; 23: 4442-52; PMID: 16 0 0 5749; http://dx.doi.org/10.1016/j.vaccine.2005.03.042 (Pubitemid 40991230)
8. Coller BA, Clements DE, Bett AJ, Sagar SL, Ter Meulen JH. The development of recombinant sub-unit envelope-based vaccines to protect against dengue virus induced disease. Vaccine 2011; 29: 7267-75; PMID: 21777637; http://dx.doi.org/10.1016/j. vaccine.2011.07.021
9. Durbin A P, Whitehead SS. Next-generation dengue vaccines: novel strategies currently under development. Viruses 2011; 3: 1800-14; http://dx.doi.org/10.3390/v3101800; PMID: 22069516
10. Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J. From research to phase III: pre-clinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29: 7229-41; PMID: 21745521; http://dx.doi.org/10.1016/j.vaccine.2011.06.094
11. Kliks S. Antibody-enhanced infection of monocytes as the pathogenetic mechanism for severe dengue illness. AIDS Res Hum Retroviruses 1990; 6: 993-8; PMID: 2223245 (Pubitemid 20300059)
12. Beckett CG, Tjaden J, Burgess T, Danko JR, Tamminga C, Simmons M, et al. Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 2011; 29: 960-8; http://dx.doi.org/10.1016/j.vaccine.2010.11.050; PMID: 21111785
13. Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, Dawes G, et al. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 2006; 353: 166-73; http://dx.doi.org/10.1016/j. virol.2006.05.005; PMID: 16814355 (Pubitemid 44291778)
14. Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, Hayes CG, et al. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 2000; 18: 2426-34; PMID: 10738100; http://dx.doi.org/10.1016/S0264-410X(99)00570-8 (Pubitemid 30156814)
15. Raviprakash K, Luke T, Doukas J, Danko J, Porter K, Burgess T, et al. A dengue DNA vaccine formulated with Vaxfectin (®) is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits. Hum Vaccin Immunother 2012; 8: 1764-8; PMID: 23032166; http://dx.doi.org/10.4161/hv.21806
16. Holman DH, Wang D, Raviprakash K, Raja NU, Luo M, Zhang J, et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vaccine Immunol 2007; 14: 182-9; PMID: 17192403; http://dx.doi.org/10.1128/CVI.00330-06 (Pubitemid 46407071)
17. Raviprakash K, Wang D, Ewing D, Holman DH, Block K, Woraratanadharm J, et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J Virol 2008; 82: 6927-34; PMID: 18480438; http://dx.doi.org/10.1128/J V I.02724-07 (Pubitemid 351977713)
18. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, Hoke CH, et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 1996; 174: 1176-84; PMID: 8940206; http://dx.doi. or g/10.10 93/i n f d i s/174. 6.1176 (Pubitemid 26393894)
19. Fraenkel-Conrat H, Mecham DK. The reaction of formaldehyde with proteins; demonstration of inter-molecular cross-linking by means of osmotic pressure measurements. J Biol Chem 1949; 177: 477-86; PMID: 18107450
20. Mason JT, O'Leary TJ. Effects of formaldehyde fixation on protein secondary structure: a calorimetric and infrared spectroscopic investigation. J Histochem Cytochem 1991; 39: 225-9; PMID: 1987266; http://dx.doi.org/10.1177/39. 2.1987266
21. Nowace, JM. Fixation and Tissue Processing. 2 010 ;141-152
22. Raviv Y, Viard M, Bess JW Jr., Chertova E, Blumenthal R. Inactivation of retroviruses with preservation of structural integrity by targeting the hydrophobic domain of the viral envelope. J Virol 2005; 79: 12394-400; PMID: 16160166; http://dx.doi.org/10.1128/JVI.79.19.12394-12400.2005 (Pubitemid 41346101)
23. Hanson CV, Riggs JL, Lennette EH. Photochemical inactivation of DNA and RNA viruses by psoralen derivatives. J Gen Virol 1978; 40: 345-58; PMID: 211184; http://dx.doi.org/10.1099/0022-1317-40-2-345 (Pubitemid 8389180)
24. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380: 1559-67; http://dx.doi.org/10.1016/S0140-6736(12)61428-7; PMID: 22975340
25. Hilleman MR. Hepatitis and hepatitis A vaccine: a glimpse of history. J Hepatol 1993; 18(Suppl 2):S5-10; PMID: 818 2 2 74; http://dx.doi.org/10.1016/ S0168-8278(05)80370-8
26. Barrett PN, Dorner F, Plotkin SA. Tick-Borne Encephalitis Vaccine. Vaccines, 3rd Ed. Editors Plotkin SA and Orenstein WA, 767-780 (1999).
27. Tsai TF. C. G. a. Y. Y. Japanese encephalitis vaccines. Vaccines, 3rd Ed. Editors Plotkin SA and Orenstein WA, 672-710 (1999).
28. Murdin AD, Inactivated Virus Vaccines RBSS. New Vaccine Technologies, Ed: Ellis RW., 133-150 (2001).
29. Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, Truong T, et al. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am J Trop Med Hyg 1996; 55: 504-10; PMID: 8940981 (Pubitemid 26392713)
30. Brown F. Review of accidents caused by incomplete inactivation of viruses. Dev Biol Stand 1993; 81: 103-7; PMID: 8174792
31. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969; 89: 422-34; PMID: 4305198
32. Gaspar LP, Mendes YS, Yamamura AM, Almeida LF, Caride E, Gonçalves RB, et al. Pressure-inactivated yellow fever 17DD virus: implications for vaccine development. J Virol Methods 2008; 150: 57-62; PMID: 18420285; http://dx.doi.org/10.1016/j. jviromet.2008.03.002
33. Maves RC, Castillo Oré RM, Porter KR, Kochel TJ. Immunogenicity of a psoralen-inactivated dengue virus type 1 vaccine candidate in mice. Clin Vaccine Immunol 2010; 17: 304-6; PMID: 20007362; http://dx.doi.org/10.1128/CVI. 00353-09
34. Maves RC, Oré RM, Porter KR, Kochel TJ. Immunogenicity and protective efficacy of a pso-ralen-inactivated dengue-1 virus vaccine candidate in Aotus nancymaae monkeys. Vaccine 2011; 29: 2691-6; PMID: 21303709; http://dx.doi.org/10.1016/j. vaccine.2011.01.077
35. Raviv Y, Blumenthal R, Tompkins SM, Humberd J, Hogan RJ, Viard M. Hydrophobic inactivation of influenza viruses confers preservation of viral structure with enhanced immunogenicity. J Virol 2008; 82: 4612-9; PMID: 18305038; http://dx.doi.org/10.1128/JVI.02233-07 (Pubitemid 351563697)
36. Sharma A, Gupta P, Glass PJ, Parker MD, Maheshwari RK. Safety and protective efficacy of INA-inactivated Venezuelan equine encephalitis virus: implication in vaccine development. Vaccine 2 011; 2 9: 9 53 - 9; PMID: 21115 0 4 8; http://dx.doi.org/10.1016/j.vaccine.2010.11.033
37. Sagripanti JL, Marschall HJ, Voss L, Hülseweh B. Photochemical inactivation of alpha- and pox-viruses. Photochem Photobiol 2011; 87: 1369-78; ht t p://dx.doi.org/10.1111/j.1751-1097.2011.0 0998.x; PMID: 21895667
38. Raviprakash K, Porter KR, Kochel TJ, Ewing D, Simmons M, Phillips I, et al. Dengue virus type 1 DNA vaccine induces protective immune responses in rhesus macaques. J Gen Virol 2000; 81: 1659-67; PMID: 10859370 (Pubitemid 30427070)
39. Chen L, Ewing D, Subramanian H, Block K, Rayner J, Alterson KD, et al. A heterologous DNA prime-Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J Virol 2007; 81: 11634-9; PMID: 17 7 152 2 4; http://dx.doi.org/10.1128/JVI.00996-07 (Pubitemid 47623795)